Treatment > Carmustine · Temozolomide Clinical Trials

Abstract

Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas

Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS

Department of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA

Both Gliadel wafers [1,3-bis(2-chloroethyl)-1-nitrosourea] and temozolomide (TEMO) have been shown in independent studies to prolong survival of patients with recurrent malignant glioma following surgery and radiotherapy.
On the basis of preclinical evidence of synergism between Gliadel wafers and TEMO, a phase I study was designed to evaluate the toxicity of combining these 2 agents in the treatment of patients with recurrent supratentorial malignant glioma.
All patients had surgical resection of the tumor at relapse, and up to 8 Gliadel (3.85%) wafers were placed in the surgical cavity following resection.
Two weeks after surgery, TEMO was given orally daily for 5 days.
Cohorts of 3 patients received TEMO at daily doses of 100 mg/m2, 150 mg/m2, and 200 mg/m2, respectively.
Patients were assessed for toxicity 4 weeks after start of the first course of TEMO.
Contrast-enhanced MRI of the brain was used to assess tumor response after the first cycle of TEMO. 
Patients with stable disease or response after the first cycle of TEMO were allowed to continue treatment at the same dose every 4 weeks for 12 cycles or until disease progression or unacceptable toxicity. 
Ten patients with a median age of 47 years (range, 22-66 years) were enrolled in this study. 
There were 7 patients with glioblastoma multiforme and 3 patients with anaplastic astrocytoma. 
Three patients were treated with TEMO at the first dose level of 100 mg/m2, 4 at the second dose level of 150 mg/m2, and 3 at the third dose level of 200 mg/m2. 
The 10 patients received a median of 3 cycles (range, 1-12 cycles) of TEMO following placement of Gliadel wafers. 
The treatment was well tolerated, with only 1 patient suffering grade III thrombocytopenia at the highest dose level. 
Two patients at each dose level had no evidence of disease progression after treatment. 
Four patients suffered progressive disease on therapy. 
Our study demonstrates that TEMO can be given safely after placement of Gliadel (3.85%) wafers. 
The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days.

PMID: 11584894 [PubMed - indexed for MEDLINE]